Immunocore Holdings plc American Depositary Receipt (6YG)
XDUS 
Summary
6YG Chart
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?
Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-2026 data could add further upside.
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum
Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?
Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.
Immunocore Holdings plc American Depositary Receipt (6YG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Immunocore Holdings plc American Depositary Receipt ever had a stock split?
Immunocore Holdings plc American Depositary Receipt Profile
| Biotechnology Industry | Healthcare Sector | Bahija Jallal CEO | XDUS Exchange | US45258D1054 ISIN |
| GB Country | 524 Employees | - Last Dividend | - Last Split | 5 Feb 2021 IPO Date |
Overview
Immunocore Holdings plc is a pioneering commercial-stage biotechnology entity that specializes in pioneering immunotherapies for combatting cancer, infectious diseases, and autoimmune disorders. Having been in operation since 1999 and based in Abingdon, the United Kingdom, Immunocore stands at the forefront of developing treatments designed to leverage the body's immune system to fight diseases. Its reputation is bolstered by its advancement in the biotechnological field, marked by significant strides in the development, clinical trials, and commercialization of therapies aimed at various challenging medical conditions.
Products and Services
- KIMMTRAK: This product is a forefront therapy offered by Immunocore for patients grappling with unresectable or metastatic uveal melanoma, showcasing the company's dedication to addressing rare cancers.
- Tebentafusp: At a Phase 2/3 clinical trial stage, this therapy is being evaluated for its effectiveness in treating advanced cutaneous melanoma, indicating Immunocore's commitment to innovating in the oncology sector.
- IMC-F106C: Currently in Phase 3 clinical trial for first-line treatment of advanced cutaneous melanoma and in Phase 1/2 for several tumor types including ovarian, non-small cell lung, and endometrial carcinoma, showcasing Immunocore's diversified approach to cancer treatment.
- IMC-R117C: This potential treatment is in phase 1 clinical trials, targeting colorectal and gastrointestinal cancers, further expanding the company's oncology pipeline.
- IMC-M113V: Still in its early phase 1 clinical trial, this treatment is being explored for human immunosuppression virus, illustrating Immunocore's venture into infectious disease treatment.
- IMC-I109V: In Phase I clinical trial aimed at patients with chronic hepatitis B virus, this therapy represents the company’s effort to tackle viral infections.
- IMC-T119C: Currently in the preclinical trial stage for addressing multiple solid tumor cancers, it underscores Immunocore's ongoing research and development in oncology.
- IMC-P115C: This candidate is also in the preclinical trial phase focusing on various solid tumor cancers, reinforcing the company's strong position in the cancer research domain.
- IMC-S118AI: Aiming to combat type 1 diabetes and still in preclinical trial, it marks Immunocore's entry into autoimmune disease treatment, showcasing its diverse research and development endeavors.
